Patent: 6,143,524

Summary for Patent: 6,143,524

Title:	Peptide and protein fusions to thioredoxin, thioredoxin-like molecules, and modified thioredoxin-like molecules
Abstract:	Provided is a fusion molecule comprising a DNA sequence encoding a thioredoxin-like protein fused to a DNA sequence encoding a second peptide or protein. The peptide or protein may be fused to the amino terminus of the thioredoxin-like molecule, the carboxyl terminus of the thioredoxin-like molecule, or within the thioredoxin-like molecule, for example at the active-site loop of the molecule. The fusion molecule may be modified to introduce one or more metal-binding/chelating amino-acid residues to aid in purification. Expression of this fusion molecule under the control of a regulatory sequence capable of directing its expression in a desired host cell, produces high levels of stable and soluble fusion protein. The fusion protein, located in the bacterial cytoplasm, may be selectively released from the cell by osmotic shock or freeze/thaw procedures. It may be optionally cleaved to liberate the soluble, correctly folded heterologous protein from the thioredoxin-like portion.
Inventor(s):	McCoy; John (Reading, MA), DiBlasio-Smith; Elizabeth (Tyngsboro, MA), Grant; Kathleen (Salem, MA), LaVallie; Edward R. (Tewksbury, MA)
Assignee:	Genetics Institute, Inc. (Cambridge, MA)
Application Number:	08/810,436
Patent Claims:	see list of patent claims

Details for Patent 6,143,524

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Wyeth Pharmaceuticals Inc.	NEUMEGA	oprelvekin	For Injection	103694	11/25/1997		2011-02-06

International Patent Family for US Patent 6,143,524

Country	Patent Number	Estimated Expiration
Austria	237692
Austria	456661
Australia	1399495
Australia	1467192
Australia	4781493
Australia	663489
Canada	2093643